Movement Alert｜Kelun-Biotech Rises 7.35% in Regular Trading, Receives RMB 7.03 Billion Settlement Payment from Yilian Biopharmaceutical

Market Focus

Jun 12

On June 12, Kelun-Biotech rose 7.35% in regular trading, trading at HKD 422.6/share, with turnover of HKD 181 million.

On the news front, the company announced that it has received settlement payments totaling RMB 702.7 million from Suzhou Yilian Biopharmaceutical pursuant to a settlement agreement signed in December 2025. The latest tranche includes RMB 602.5 million representing Kelun-Biotech's share of revenue from Yilian's YL201 (B7H3) out-licensing transaction. According to the parent company Kelun Pharmaceutical's disclosure, the settlement covers revenue sharing from six pipeline assets including YL201, YL202, YL211, YL212, YL221, and YL222. The substantial cash inflow is expected to meaningfully improve the company's cash position and enhance R&D funding capacity, with a positive impact on full-year financial performance.

The broader Biotechnology sector also traded higher, with AKESO up 6.09%, Remegen up 5.24%, Innovent Bio up 5.21%, 3SBio up 3.14%, and BeiGene up 1.8%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1155839859"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1155839859\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1155839859?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 11:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155839859","market":"us","top_or_hot":-1,"title":"Movement Alert｜Kelun-Biotech Rises 7.35% in Regular Trading, Receives RMB 7.03 Billion Settlement Payment from Yilian Biopharmaceutical","media":"Market Focus","content":"<p><p>On June 12, Kelun-Biotech rose 7.35% in regular trading, trading at HKD 422.6/share, with turnover of HKD 181 million.</p><p>On the news front, the company announced that it has received settlement payments totaling RMB 702.7 million from Suzhou Yilian Biopharmaceutical pursuant to a settlement agreement signed in December 2025. The latest tranche includes RMB 602.5 million representing Kelun-Biotech's share of revenue from Yilian's YL201 (B7H3) out-licensing transaction. According to the parent company Kelun Pharmaceutical's disclosure, the settlement covers revenue sharing from six pipeline assets including YL201, YL202, YL211, YL212, YL221, and YL222. The substantial cash inflow is expected to meaningfully improve the company's cash position and enhance R&D funding capacity, with a positive impact on full-year financial performance.</p><p>The broader Biotechnology sector also traded higher, with AKESO up 6.09%, Remegen up 5.24%, Innovent Bio up 5.21%, 3SBio up 3.14%, and BeiGene up 1.8%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Kelun-Biotech Rises 7.35% in Regular Trading, Receives RMB 7.03 Billion Settlement Payment from Yilian Biopharmaceutical</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Kelun-Biotech Rises 7.35% in Regular Trading, Receives RMB 7.03 Billion Settlement Payment from Yilian Biopharmaceutical\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-12 11:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 12, Kelun-Biotech rose 7.35% in regular trading, trading at HKD 422.6/share, with turnover of HKD 181 million.</p><p>On the news front, the company announced that it has received settlement payments totaling RMB 702.7 million from Suzhou Yilian Biopharmaceutical pursuant to a settlement agreement signed in December 2025. The latest tranche includes RMB 602.5 million representing Kelun-Biotech's share of revenue from Yilian's YL201 (B7H3) out-licensing transaction. According to the parent company Kelun Pharmaceutical's disclosure, the settlement covers revenue sharing from six pipeline assets including YL201, YL202, YL211, YL212, YL221, and YL222. The substantial cash inflow is expected to meaningfully improve the company's cash position and enhance R&D funding capacity, with a positive impact on full-year financial performance.</p><p>The broader Biotechnology sector also traded higher, with AKESO up 6.09%, Remegen up 5.24%, Innovent Bio up 5.21%, 3SBio up 3.14%, and BeiGene up 1.8%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"","article_id":"1155839859","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155839859","pubTimestamp":1781233334,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 12, Kelun-Biotech rose 7.35% in regular trading, trading at HKD 422.6/share, with turnover of HKD 181 million.On the news front, the company announced that it has received settlement payments...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物"},"translate_title":"动静快讯|科伦生物常规盘涨7.35%获亿联生物制药70.3亿结算款","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1},"content_text":"On June 12, Kelun-Biotech rose 7.35% in regular trading, trading at HKD 422.6/share, with turnover of HKD 181 million.On the news front, the company announced that it has received settlement payments totaling RMB 702.7 million from Suzhou Yilian Biopharmaceutical pursuant to a settlement agreement signed in December 2025. The latest tranche includes RMB 602.5 million representing Kelun-Biotech's share of revenue from Yilian's YL201 (B7H3) out-licensing transaction. According to the parent company Kelun Pharmaceutical's disclosure, the settlement covers revenue sharing from six pipeline assets including YL201, YL202, YL211, YL212, YL221, and YL222. The substantial cash inflow is expected to meaningfully improve the company's cash position and enhance R&D funding capacity, with a positive impact on full-year financial performance.The broader Biotechnology sector also traded higher, with AKESO up 6.09%, Remegen up 5.24%, Innovent Bio up 5.21%, 3SBio up 3.14%, and BeiGene up 1.8%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}